Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy

Cancer Research

Volumn 59, Issue 6, 1999, Pages 1236-1243

  Yang, Xiao Dong ^a   Jia, Xiao Chi ^a   Corvalan, Jose R F ^a   Wang, Ping ^a   Davis, C Geoffrey ^a   Jakobovits, Aya ^a  

^a Abgenix Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY E7.6.3; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOLOGY; CONTROLLED STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSPLANTATION, HETEROLOGOUS;

EID: 0033559606     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Ullrich, A., and Schlessinger, J. Signal transduction by receptors with tyrosine kinase activity. Cell, 61: 203-212, 1990.
2. Baselga, J., and Mendelsohn, J. Receptor blockade with monoclonal antibodies as anti-cancer therapy. Pharmacol. Ther. 64: 127-154, 1994.
3. Mendelsohn, J., and Baselga, J. Antibodies to growth factors and receptors. In: V. T. DeVita, S. Hellman, and S. A. Rosenberg (eds.), Biologic Therapy of Cancer, pp. 607-623. Philadelphia: J. B. Lippincott Company, 1995.
4. Fan, Z., and Mendelsohn, J. Therapeutic application of anti-growth factor receptor antibodies. Curr. Opin. Oncol., 10: 67-73, 1998.
5. Riedel, H., Massoglia, S., Schlessinger, J., and Ullrich, A. Ligand activation of overexpressed epidermal growth factor receptors transforms NIH 3T3 mouse fibroblasts. Proc. Natl. Acad. Sci. USA, 85: 1477-1481, 1988.
6. Modjtahedi, H., and Dean, C. The receptor for EGF and its ligands: expression, prognostic value and target for therapy in cancer. Intl. J. Oncol., 4: 277-296, 1994.
7. Gullick, W. J. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br. Med. Bull., 47: 87-98, 1991.
8. Salomon, D. S., Brandt, R., Ciardiello, F., and Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol., 19: 183-232, 1995.
9. Aboud-Pirak, E., Hurwitz, E., Pirak, M. E., Bellot, F., Schlessinger, J., and Sela, M. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J. Natl. Cancer Inst., 80: 1505-1611, 1988.
10. Modjtahedi, H., Styles, J. M., and Dean, C. J. The human EGF receptor as a target for cancer therapy: six new rat mAbs against the receptor on the breast carcinoma MDA-MB 468. Br. J. Cancer, 67: 247-253, 1993.
11. Modjtahedi, H., Eccles, S., Box, G., Styles, J., and Dean, C. Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction. Br. J. Cancer, 67: 254-261, 1993.
12. Fan, Z., Baselga, J., Masui, H., and Mendelsohn, J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res., 53: 4637-4642, 1993.
13. Baselga, J., Norton, L., Masui, H., Pandiella, A., Coplan, K., Miller, W. H., and Mendelsohn, J. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J. Natl. Cancer Inst., 85: 1327-1333, 1993.
14. Goldstein, N. I., Prewett, M., Zuklys, K., Rockwell, P., and Mendelsohn, J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res., 1: 1311-1318, 1995.
15. Prewett, M., Rockwell, R., Rockell, R. F., Giorgio, N. A., Mendelsohn, J., Scher, H. I., and Goldstein, N. I. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J. Immunother. Emphasis Tumor Immunol., 19: 419-427, 1996.
16. Slovin, S. F., Kelley, W. K., Cohen, R., Cooper, M., Malone, T., Weingard, K., Waksal, H., Falcey, J., Mendelsohn, J., and Scher, H. I. Epidermal growth factor receptor (EGF-r) monoclonal antibody (MoAb) C225 and doxorubicin (DOC) in androgen-indcpendent (AI) prostate cancer (PC): results of a phase Ib/IIa study. Proc. Am. Soc. Clin. Oncol., 16: 311, 1997.
17. Falcey, J., Pfister, D., Cohen, R., Cooper, M., Bowden, C., Burtness, B., Mendelsohn, J., and Waksal, H. A study of anti-epidermal growth factor receptor (EGFr) monoclonal antibody C225 and cisplatin in patients (pts) with head and neck or lung carcinomas. Proc. Am. Soc. Clin. Oncol., 16: 383, 1997.
18. Mendez, M. J., Green, L. L., Corvalan, J. R. F., Jia, X-C., Maynard-Currie, C. E., Yang, X-D., Gallo, M. L., Louie, D. M., Lee, D. V., Erickson, K. L., Luna, J., Roy, C. M-N., Ahderrahim, H., Kirschenbaum, F., Noguchi, M., Smith, D. H., Fukushima, A., Hales, J. F., Klaphok, S., Finer, M. H., Davis, C. G., Zsebo, K. M., and Jakobovits, A. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat. Genet., 15: 146-156, 1997.
19. Jakobovits, A. The long-awaited magic bullets: therapeutic human monoclonal antibodies from transgenic mice. Exp. Opin. Invest. Drugs, 7: 607-614, 1998.
20. Debanne, M. T., Pacheco-Oliver, M. C., and O'Connor-McCourt, M. D. Purification of the extracellular domain of the epidermal growth factor receptor produced by recombinant baculovirus-infected insect cells in a 10-L reactor. In: C. D. Richardson (ed.), Baculovirus Expression Protocols, pp. 349-361. Totowa, NJ: Humana Press Inc., 1995.
21. Ishiyama, M., Tominaga, H., Shiga, M., Sasamoto, K., Ohkura, Y., and Ueno, K. A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. Biol. Pharmacol. Bull., 19: 1518-1520, 1996.
22. McConnell, H. M., Owicki, J. C., Parce, J. W., Miller, D. L., Baxter, G. T., Wada, H. G., and Pitchford, S. The cytosensor microphysiometer: biological applications of silicon technology. Science (Washington DC), 257: 1906-1912, 1992.
23. Bogovski, P. Tumours of the skin. In: V. S. Turusov and U. Mohr (eds.), Tumours of Mouse, pp. 1-26. Lyon, France: IARC Scientific Publications, 1994.
24. Ennis, B. W., Valverius, E. M., Bates, S. F., Lippman, M. E., Bellot, F., Kris, R., Schlessinger, J., Masui, H., Goldenberg, A., Mendelsohn, J., and Dickson, R. B. Anti-epidermal growth factor receptor antibodies inhibit the autocrine-stimulated growth of MDA-168 human breast cancer cells. Mol. Endocrinol., 3: 1830-1838, 1989.
25. Kawamoto, T., Mendelsohn, J., Gordon, A. L., Sato, G. H., Lazar, C. S., and Gill, G. N. Relation of epidermal growth factor receptor concentration to growth of human epidermoid carcinoma A431 cells. J. Biol. Chem., 259: 7761-7766, 1984.
26. Masui, H., Moroyama, T., and Mendelsohn, J. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes. Cancer Res., 46: 5592-5598, 1986.
27. Wu, X., Fan, Z., Masui, H., Rosen, N., and Mendelsohn, J. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in human colorectal carcinoma cell line and its delay by insulin. J. Clin. Invest., 95: 1897-1905, 1995.
28. Sturgis, E. M., Sacks, P. G., Masui, H., Mendelsohn, J., and Schantz, S. P. Effects of antiepidermal growth factor receptor antibody 528 on the proliferation and differentiation of head and neck cancer. Otolaryngol. Head Neck Surg., 111: 633-643, 1994.
29. Modjtahedi, H., Eccles, S., Sandle, J., Box, G., Titley, J., and Dean, C. Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor. Cancer Res., 54: 1695-1701, 1994.
30. Viloria Petit, A. M., Rak, J., Hung, M-C., Rockwell, P., Goldstein, N., Fendly, B., and Kerbel, R. S. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol., 151: 1523-1530, 1997.
31. Kita, Y., Tseng, J., Horan, T., Wen, J., Philo, J., Chang, D., Ratzkin, B., Pacifici, R., Brankow, D., Hu, S., Luo, Y., Wen, D., Arakawa, T., and Nicolson, M. ErbB receptor activation, cell morphology changes, and apoptosis induced by anti-Her2 monoclonal antibodies. Biochem. Biophys. Res. Commun., 226: 59-69, 1996.
32. ™ (human anti-Her2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (Her2+/mbc) markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Proc. Am. Soc. Clin. Oncol., 17: 98, 1998.
33. ™ (humanized anti-Her2 antibody) as a single agent in 222 women with Her2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc. Am. Soc. Clin. Oncol., 17: 97, 1998.